Letrozole Viatris

Letrozole, the active ingredient in Letrozole Viatris, is an aromatase inhibitor presented as an oral tablet for oral use. It reduces estrogen production and is used to treat hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozole Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The product conforms to EU quality standards and is manufactured under GMP conditions. It is distributed through GNH USA's global network, ensuring reliable supply chains and regulatory compliance for oncology treatments.

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer. - Hormone receptor‑positive breast cancer (postmenopausal): Reduces risk of disease recurrence and progression. - Metastatic breast cancer (postmenopausal): Improves disease control and prolongs survival. - Adjuvant therapy for early‑stage hormone‑dependent breast cancer (postmenopausal): Decreases likelihood of tumor regrowth after surgery.

Letrozole may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hot flashes: Sudden feeling of warmth and sweating. - Arthralgia: Joint pain or stiffness. - Fatigue: Persistent tiredness affecting daily activities. - Nausea: Mild to moderate upset stomach. - Headache: Pressure or throbbing pain in the head. - Dizziness: Light‑headed sensation, especially when standing.

Serious or Rare Side Effects: - Bone fracture: Increased risk due to reduced bone mineral density. - Deep vein thrombosis: Blood clot formation in deep veins. - Severe allergic reaction: Rash, swelling, or difficulty breathing. - Hepatic dysfunction: Elevated liver enzymes or jaundice. - QT interval prolongation: Potential cardiac rhythm disturbances.

Before initiating Letrozole therapy, several safety considerations should be addressed. - Bone health monitoring: Assess bone mineral density regularly due to risk of osteoporosis. - Liver function testing: Perform baseline and periodic liver enzyme assessments. - Cardiovascular risk evaluation: Consider history of thromboembolic events. - Pregnancy avoidance: Do not use in pregnant or nursing women; effective contraception required. - Drug interaction review: Avoid concomitant estrogen replacement therapy. - Store at ambient temperature: Keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Letrozole can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Estrogen replacement therapy: Counteracts letrozole's estrogen‑lowering effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole): May increase letrozole plasma levels. - Tamoxifen: Simultaneous use can reduce therapeutic benefit.

Moderate Interactions (Monitor Closely): - CYP2A6 inhibitors (e.g., methoxsalen): May modestly raise letrozole concentrations. - Warfarin: Potential alteration of anticoagulant effect; monitor INR. - Cholesterol‑lowering agents (e.g., statins): Observe for any changes in lipid profile.